Big pharma Bristol-Myers Squibb’s (BMY) new drug Opdivo scored another win Monday, as a late-stage trial in kidney cancer was stopped early because it had already hit its endpoint. Small biotech Exelixis (EXEL) also reported success in a kidney-cancer trial, driving its embattled stock up 50%. Bristol-Myers’ trial, called Checkmate-025, compared Opdivo with everolimus, better known as Novartis’ (NVS) Afinitor, in patients with advanced or
Big pharmas Merck (MRK) and Bristol-Myers Squibb (BMY) released new data on their hot new immunotherapy cancer drugs Friday afternoon, but the results sent their stocks in opposite directions. Bristol’s stock dropped 6.6% after the release of two late-breaker abstracts on studies of its drug Opdivo, a PD-1 inhibitor, for the American Society of Clinical Oncology (ASCO) meeting that opened Friday and will continue through the weekend. The study
The anti-PD-1 class of cancer fighters continued to shine at a major medical meeting Monday, though analysts continued to debate just how wide a population they can eventually treat. On Monday morning at the American Association for Cancer Research (AACR) meeting in Philadelphia, Bristol-Myers Squibb (BMY) reported positive midstage trial results for the combo of its new anti-PD-1 Opdivo with its older drug Yervoy in treated advanced melanoma. The